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Treatment for cocaine  
dependence: reviewing  
current evidence
I  Problem cocaine use and treatment in Europe
Despite declining or stable levels of cocaine use in most 
countries, an estimated 2.2 million young adults (aged 
15–34) used the drug in the last year. While many cocaine 
users will not experience problems related to consumption, 
a small but significant minority will be in contact with drug 
services because of health-related problems linked to the drug 
itself and the route of administration. These can range from 
problems with dependence, to cardiovascular and mental 
health issues, to blood borne viral infections such as human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV) 
(EMCDDA, 2014). In the European Union 55 000 (14 %) of all 
reported clients entering specialised drug treatment in 2012 
reported cocaine as their primary drug. Given the prevalence 
of cocaine use, the number entering treatment and the 
different types of cocaine users finding effective treatments is 
an ongoing priority.
I  Types of pharmacological treatments  
Pharmacological treatment options available for clients 
with heroin problems have been available in drug treatment 
services in much of Europe for a number of decades, 
most commonly provided in the form of methadone and 
buprenorphine. However, such a medical solution has so far 
been elusive for treating clients with problems linked with the 
use of illicit stimulants, such as cocaine and amphetamines. 
Nevertheless, a number of medications have been examined 
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to explore whether they may play a role in the spectrum 
of treatment options being offered for cocaine problems. 
These medications have been registered for a range of 
other medical conditions (see figure) and were not originally 
proposed for the treatment of cocaine users. As such, the 
drugs are being used in an ‘off-label’ (not indicated) way in 
trials. In general, these medications are used to treat cocaine 
users in conjunction with various psychosocial interventions, 
such as contingency management (see ‘Psychosocial 
interventions for treating cocaine problems’).
Psychiatric and anticonvulsant medications, and several other 
classes of drugs that modulate the brain’s dopamine system, 
have been examined to establish whether they can be used 
to treat cocaine problems. These drugs can help to regulate 
the systems in the human brain that carry neurotransmitters, 
which are naturally occurring chemicals within the brain 
used to control and regulate psychological and physical 
functions (see video online). Cocaine blocks the uptake of a 
neurotransmitter called dopamine. As this depletes the level 
of dopamine available in the brain, medications that can halt 
this process and alleviate its side effects are considered the 
most promising in the treatment of cocaine users. 
Two types of psychiatric medications, antidepressants and 
antipsychotics, have been studied in the treatment of cocaine 
users. Antidepressants are normally used to treat people 
suffering from depressive disorders. Cocaine use can lead 
to depression because it affects the monoamine system 
(involved in mood regulation). For this reason antidepressants 
have been tested among cocaine users to see if they can 
reduce short-term post-cocaine depression and craving. 
Antipsychotic medications are used to treat mental 
disorders, such as schizophrenia and bipolar disorders (in 
particular, manic episodes). Studies have been undertaken 
to evaluate their role in treating cocaine users experiencing 
hallucinations, delusions and other psychotic symptoms.
Use of cocaine may enhance dopamine transmission 
and deplete dopamine concentrations in the brain. As 
a result, dopamine agonists could, theoretically, reduce 
these symptoms in cocaine users. Central nervous system 
stimulants are used to treat conditions such as attention 
deficit hyperactivity disorder (ADHD). In particular, these 
stimulants indirectly increase dopamine and, if administered 
orally along with long-lasting compounds, can counteract the 
depletion of dopamine that arises from cocaine addiction. As 
a result, a number of these stimulants have been tested to 
see if they can work as substitution treatments for cocaine 
users.
Medications from several different classes of drugs have been 
identified as potential treatments for cocaine users as a result 
of their ability to block the release of the neurotransmitter 
dopamine within the brain. This includes anticonvulsants, 
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Disulfiram, and opioid receptor antagonists. Anticonvulsant 
(or antiepileptic) medications are used to treat seizures in 
people with epilepsy. As these drugs are supposed to balance 
the dopamine system and effectively block the addiction-
related effects of cocaine, some studies have examined their 
use in treating cocaine users. Disulfiram is one of several 
medications that have been used to treat alcoholism. It 
inhibits an enzyme involved in the metabolism of alcohol, 
making the experience of drinking very unpleasant, which 
is intended to discourage its consumption. Recent studies 
have indicated that Disulfiram can be used to treat cocaine 
addiction as its mechanism of action results in a modulation 
of dopamine in users’ brains. Naltrexone has been used in 
the treatment of alcoholism and, to a lesser extent, in the 
management of opioid dependence. It is an opioid receptor 
antagonist and can reduce cocaine craving and relapse rates 
among dependent users.
I  What can research tell us?
As highlighted above, a number of medications have been 
trialled, but is there any evidence of their effectiveness in 
treating cocaine dependence and related problems? In order 
to try to answer this question, six systematic reviews of 
the research examining the use of medications for treating 
cocaine dependency have been undertaken by the Cochrane 
Group on Drugs and Alcohol (www.cochrane.org; cdag.
cochrane.org/our-reviews). These reviews attempt to make 
sense of the results of all the individual studies for each class 
of drug published between 1985 and 2010. This covered 
92 individual studies, 85 of which were conducted in the 
United States, and included a total of 7 363 participants. This 
summary presents a meta-analysis of the original reviews, 
in order to clarify the role played by the drugs and to identify 
which are most effective (Amato et al., 2007; Minozzi et al., 
2008; Castells et al., 2010; Pani et al., 2010; Amato et al., 
2011; Pani et al., 2011). Three statistical techniques have 
been used to assess the reviews and examine the main 
results for patients. Multiple-treatment meta-analysis (MTM) 
allowed comparison of interventions across studies; surface 
under the cumulative ranking curve analysis (SUCRA) 
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involved ranking the competing treatments according to the 
study outcome; while pair-wise meta-analysis was used to 
compare the experimental interventions against controls. 
These statistical methods were used to explore whether 
different medications were associated with three outcomes: 
reducing the use of cocaine, reducing cocaine-related craving 
and retention of cocaine users in the treatment programme.
These statistical techniques produced mixed results for the 
efficacy of medications in reducing cocaine use, as shown in 
the table.
Overall, antipsychotic medications appeared the most 
effective at reducing users’ cravings for cocaine. Here, MTM 
showed statistically significant results that antipsychotic and 
antidepressant drugs were effective when compared with 
placebo. Similarly, in the analysis of the ranking (SUCRA) 
with all the other medications, the antipsychotic drugs 
scored highest (97 %) at reducing craving. The pair-wise 
meta-analysis also showed that the antipsychotic drugs had 
a limited, but statistically significant, advantage over placebo 
and over anticonvulsants
Patient drop-out levels, or the number of patients leaving the 
studies before their conclusion, were used as a measure of 
acceptability of interventions to cocaine users. A mixed set 
of results was generated by the MTM analysis for this issue. 
Disulfiram was better than placebo, versus anticonvulsants, 
and versus antidepressants, at retaining users in treatment. 
Patients given opioid antagonists remained in treatment 
for longer periods than those given anticonvulsants. A 
similar picture emerged from the SUCRA ranking analysis, 
where Disulfiram and opioid antagonists were also shown 
to be better accepted treatments by users. Of these two 
medications, Disulfiram, showed more favourable results 
when the pair-wise meta-analysis of three studies comparing 
opioid antagonists versus Disulfiram was undertaken.
Statistical techniques used
Analysis Description Narrative results
MTM Comparison of 
interventions across 
different studies
None of the studied 
drugs significantly 
reduced the use of 
cocaine when they 
were compared to  
all the other  
medications and to 
placebo
SUCRA Hierarchy of the  
competing treat-
ments
Dopamine agonists 
and antipsychotic 
medications had 
the highest levels of 
efficacy for reducing 
cocaine use
Pair-wise meta-
analysis
Comparison of 
studies
None of the pharma-
cological interven-
tions were shown 
to be better than 
placebo in reducing 
the use of cocaine
I  Conclusions
To date, a range of different medications have been trialled 
to assess their use in the treatment of cocaine users. This 
has largely revolved around testing the use of medications 
established as treatments for other conditions. A mixed 
picture emerges from the systematic reviews of research 
evidence conducted to date regarding what might best be 
used to treat cocaine users. This new analysis of existing 
reviews suggests that antipsychotic medications appear 
to be the most successful at assisting users to cease use 
and overcome cravings for use, while Disulfiram is the most 
accepted treatment by users. Nonetheless, none of these 
medications has yet been established as effective treatment 
in the same rigorous way as, for example, methadone has 
been for opioid dependence. Several classes of drugs 
remain under ongoing analysis to provide treatment for 
users, and work is continuing on preventative and cessation 
measures, such as the use of a cocaine vaccine (EMCDDA, 
2010). What remains clear in the challenge of constructing 
a set of interventions for cocaine users is that psychosocial 
interventions have a proven effectiveness. When coupled 
with a suitable medication, these interventions, such as 
contingency management, may form the core components of 
an effective treatment intervention for cocaine users.
Video on treatment for cocaine dependence, available on the EMCDDA website: 
emcdda.europa.eu/topics/pods/treatments-for-cocaine-dependence
I  Interactive element: video
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In the absence of an established pharmacotherapy for 
cocaine dependency, treatment options have made use 
of psychosocial interventions. While including a range of 
different measures, these interventions can be regarded as 
being structured therapeutic processes addressing both 
psychological and social aspects of a user’s behaviour, 
varying in terms of their duration and intensity (Welsh 
Government, 2011). Three general types of psychosocial 
intervention have been used to treat drug users: cognitive 
behavioural therapy, motivational interviewing and 
contingency management. In practice there are many 
subtypes, variations and overlaps in the specific measures 
offered by service providers in different countries.  
 
Cognitive behavioural therapy (CBT) is a psychotherapeutic 
treatment modality that can be offered in an individual 
or group format (Hofmann et al., 2013). It is empirically 
supported as a treatment for substance use disorders. In 
general, CBT interventions involve challenging irrational, 
negative thinking styles that are thought to promote 
negative affective states, which in turn promote maladaptive 
behaviours. CBT interventions promote the development of 
alternative coping skills and focus on changing behaviours 
and cognitions related to substance use through self-
control training (e.g. stimulus control techniques), social 
and coping skills training and relapse prevention. Initial 
treatment sessions often involve developing skills directly 
related to achieving and maintaining abstinence (e.g. 
drug use self-monitoring, refusal and craving coping skills, 
increasing social support and non-drug-related activities, 
problem-solving training, coping with relapse). Later CBT 
sessions may focus on topics and skills indirectly related to 
maintaining abstinence (e.g. anger/frustration and anxiety/
depression management, impulse control, self-efficacy, 
effective communication).   
 
Motivational interviewing (MI) is a client-centred, semi-
directive method for enhancing intrinsic motivation to 
change by exploring and resolving ambivalence (Smedslund 
et al., 2011). It seeks to harness an individual’s motivation 
to engage with the treatment process. As a result, it is often 
used at the outset of treatment to help motivate clients to 
try more intensive measures, such as CBT. MI has been 
shown to be effective with both adults and adolescents and 
is an empirically supported intervention for substance use 
disorders. It is especially useful when clients are ambivalent 
about changing their behaviour. In providing MI-based 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
interventions, therapists ask open-ended questions, provide 
affirmations to the client, listen reflectively and summarise 
the client’s statements (Schettino et al, 2014). 
 
Contingency management (CM) is a type of treatment 
used in the mental health or substance use fields. Clients’ 
behaviours are rewarded (or, less often, punished) in line 
with treatment objectives and adherence to, or failure 
to adhere to, programme rules and regulations or their 
treatment plan (Griffith et al., 2000). Clients can be, for 
example, rewarded with vouchers that can be exchanged for 
retail items (Vocci and Montoya, 2009). 
 
Several reviews have been undertaken to examine the 
effectiveness of psychosocial interventions for treating drug 
problems. For example, a systematic review (Knapp et al., 
2007) showed that CBT interventions reduced drop-out 
from treatment and use of cocaine; this was especially 
true when accompanied by a contingency management 
approach. In particular, CM interventions have been shown 
to help to improve retention in treatment and, in turn, 
other treatment outcomes (Vocci and Montoya, 2009). 
Consequently, measures following this approach to treating 
cocaine dependency rank as the psychosocial intervention 
with the highest efficacy (Vocci and Montoya, 2009). More 
recently, a Belgian study reported that after six months 
of participation in a CM programme with community 
reinforcement, the rate of abstinence among cocaine 
users was three times higher than for clients in standard 
treatment (Vanderplasschen et al., 2011). 
 
Psychosocial interventions for treating cocaine problems  
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I  Key definitions 
The evidence in support of interventions is based on individual studies and systematic 
reviews of evidence. Generally, studies compare an experimental intervention against 
a placebo or a control intervention, rather than against other competing interventions. 
Consequently, these comparisons are of limited use in informing clinical decision-
making, which is better served by the results of so-called ‘head to head’ comparisons. 
These trials compare two medications against each other, highlighting their strengths 
and weaknesses, so the one most suited to ‘real world’ everyday use can be identified. 
Meta-analytic techniques allow us to overcome some of the problems arising from 
indirect comparisons and extract useful results from various existing studies. The three 
meta-analytic techniques used in this summary are defined below.
Multiple-treatment meta-analysis allows comparison of interventions across different 
studies (Caldwell et al., 2005). It allows us to overcome some of the problems arising 
from indirect comparisons by generating results that remain consistent across the 
protocols and inclusion/exclusion criteria for patients’ enrolment across different 
studies..
Surface under the cumulative ranking curve analysis (SUCRA)
SUCRA analysis is used to provide a hierarchy of the competing treatments. The larger 
the SUCRA value, the better the rank of the treatment (Chaimani et al., 2013).
Pair-wise meta-analysis of studies is, in contrast to the other two approaches, 
a method based on direct comparison. It involves a pooled analysis of studies 
comparing an experimental intervention against a control.
